Sagent reintroduces Adenosine injection with improved prefilled plastic syringes

For the 12 months ending February 2014, the US market for Adenosine Injection, USP approximated $28m, according to IMS.

As with all products in the company’s portfolio, Adenosine features Sagent’s PreventIV Measures packaging and labeling, in order to help reduce medication errors.

The injection is indicated for conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts.

According to the company, when clinically advisable, suitable vagal maneuvers, should be attempted prior to adenosine administration.

Sagent is mainly focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.

The company has created a different global network of resources, comprising rapid development capabilities, sophisticated manufacturing and new drug delivery technologies, which result in an expanding pharmaceutical product portfolio that fulfils the evolving needs of patients.